Holen Sie sich die Stockscreener-App
5.54
5.93%
0.31
Handel nachbörslich:
5.54
Schlusskurs vom Vortag:
$5.23
Offen:
$5.25
24-Stunden-Volumen:
865.22K
Relative Volume:
0.85
Marktkapitalisierung:
$333.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.80M
KGV:
-7.3867
EPS:
-0.75
Netto-Cashflow:
$-30.67M
1W Leistung:
+16.63%
1M Leistung:
+4.33%
6M Leistung:
+7.16%
1J Leistung:
+10.14%
1-Tages-Spanne:
$5.25
$5.65
1-Wochen-Bereich:
$4.735
$5.65
52-Wochen-Spanne:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Firmenname
Aldeyra Therapeutics Inc
Sektor
Branche
Telefon
781-761-4904
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Vergleichen Sie ALDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.54 | 314.65M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-04-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-30 | Eingeleitet | Jefferies | Buy |
| 2020-10-16 | Eingeleitet | BTIG Research | Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-04 | Eingeleitet | Citigroup | Buy |
| 2018-09-26 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Janney | Buy |
| 2018-01-26 | Eingeleitet | Seaport Global Securities | Buy |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-01 | Eingeleitet | Stifel | Buy |
| 2015-07-01 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-03-20 | Bestätigt | H.C. Wainwright | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-06-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Earnings Recap: Is Aldeyra Therapeutics Inc exposed to political riskQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
How volatile is Aldeyra Therapeutics Inc. stockJuly 2025 Selloffs & Risk Adjusted Buy and Sell Alerts - mfd.ru
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Thera - The National Law Review
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update - MarketBeat
Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily
FDA Extends Review Timeline for Aldeyra's Dry Eye Drug Candidate () - aktiencheck.de
Support Test: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus
Analysis Recap: Is Aldeyra Therapeutics Inc stock trending bullish2025 Momentum Check & Community Trade Idea Sharing Platform - baoquankhu1.vn
Insider Buy: Does National Energy Services Reunited Corp Equity Warrant stock reflect fundamentals2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Trend Review: Is Envirotech Vehicles Inc in accumulation or distribution phaseJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Will Betterware de Mxico SAPI de CV benefit from green energy policiesMarket Movers & Real-Time Stock Entry Alerts - baoquankhu1.vn
Sell Signal: What is the dividend yield of Trailblazer Merger Corporation I Equity RightJuly 2025 Update & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Weekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Market Trends: Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Portfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
Can Aldeyra Therapeutics Inc. stock rebound after recent weaknessDay Trade & Daily Entry Point Trade Alerts - Улправда
Why Aldeyra Therapeutics Inc. stock attracts high net worth investors2025 Big Picture & Weekly Momentum Stock Picks - Улправда
Growth Value: Why Aldeyra Therapeutics Inc. stock attracts high net worth investorsEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
News | postregister.comAldeyra Therapeutics, Inc.Common Stock (Nasdaq:ALDX) Detailed Stock Data - FinancialContent
(ALDX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aldeyra Therapeutics announces chief development officer resignation - MSN
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
What to keep an eye on in 2026 - Eyes On Eyecare
Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign - marketscreener.com
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com Nigeria
Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks
Aldeyra Therapeutics chief development officer to step down by March 2026 By Investing.com - Investing.com India
Aldeyra Therapeutics Announces Resignation of Chief Development Officer - TradingView — Track All Markets
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week - 富途牛牛
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Can SAL Steel Limited Maintain Growth Without Diluting ShareholdersLong-Term Investment Plans & Small Investment Capital Gains - earlytimes.in
What dividend safety score for Aldeyra Therapeutics Inc. stockMarket Trend Summary & Reliable Trade Execution Plans - DonanımHaber
What Wall Street predicts for Aldeyra Therapeutics Inc. stock priceWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being InvestigatedContact the Firm if You Lost Money - 28/22 News
Aldeyra Therapeutics Earnings Notes - Trefis
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX) - MarketBeat
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks
Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):